Mendus (IMMU) Stock Overview
A biopharmaceutical company, develops immunotherapies for the treatment of tumor recurrence and established tumors. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
IMMU Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Mendus AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 4.21 |
| 52 Week High | SEK 10.98 |
| 52 Week Low | SEK 3.90 |
| Beta | 0.70 |
| 1 Month Change | -14.71% |
| 3 Month Change | -24.78% |
| 1 Year Change | -40.01% |
| 3 Year Change | -85.24% |
| 5 Year Change | -96.60% |
| Change since IPO | -97.53% |
Recent News & Updates
Recent updates
Mendus (STO:IMMU) Is In A Good Position To Deliver On Growth Plans
Oct 16
We Think Mendus (STO:IMMU) Can Easily Afford To Drive Business Growth
Jun 13Companies Like Mendus (STO:IMMU) Can Afford To Invest In Growth
Dec 31Mendus AB (publ) (STO:IMMU) Shares Could Be 24% Above Their Intrinsic Value Estimate
Aug 31We're Keeping An Eye On Mendus' (STO:IMMU) Cash Burn Rate
Feb 20Mendus (STO:IMMU) Is Making Moderate Use Of Debt
Mar 28Is Mendus (STO:IMMU) Using Debt Sensibly?
Dec 01Is Mendus (STO:IMMU) Using Debt Sensibly?
Aug 10Health Check: How Prudently Does Immunicum (STO:IMMU) Use Debt?
May 10Is Immunicum (STO:IMMU) Using Too Much Debt?
Jan 31Shareholder Returns
| IMMU | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | 1.1% | -3.9% | -4.7% |
| 1Y | -40.0% | 2.8% | -0.6% |
Return vs Industry: IMMU underperformed the Swedish Biotechs industry which returned 2.8% over the past year.
Return vs Market: IMMU underperformed the Swedish Market which returned -0.6% over the past year.
Price Volatility
| IMMU volatility | |
|---|---|
| IMMU Average Weekly Movement | 8.3% |
| Biotechs Industry Average Movement | 8.8% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in SE Market | 12.7% |
| 10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: IMMU has not had significant price volatility in the past 3 months compared to the Swedish market.
Volatility Over Time: IMMU's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 20 | Erik Manting | www.mendus.com |
Mendus AB (publ), a biopharmaceutical company, develops immunotherapies for the treatment of tumor recurrence and established tumors. Its lead product is vididencel (DCP-001), which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia (AML); Phase II CADENCE clinical trial to treat AML; and Phase I ALISON clinical trial for the treatment of ovarian cancers. The company also develops ilixadencel, which is in phase 1/2 clinical trial for the treatment of soft tissue sarcomas; and an NK cell program, which is in a preclinical study for NK cell-based therapies.
Mendus AB (publ) Fundamentals Summary
| IMMU fundamental statistics | |
|---|---|
| Market cap | SEK 257.97m |
| Earnings (TTM) | -SEK 113.26m |
| Revenue (TTM) | n/a |
Is IMMU overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IMMU income statement (TTM) | |
|---|---|
| Revenue | SEK 0 |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 0 |
| Other Expenses | SEK 113.26m |
| Earnings | -SEK 113.26m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
Apr 17, 2026
| Earnings per share (EPS) | -1.85 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.1% |
How did IMMU perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/20 23:47 |
| End of Day Share Price | 2026/03/20 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Mendus AB (publ) is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jyoti Prakash | Edison Investment Research |
| Stefan Wård | Pareto Securities |
| Chien-Hsun Lee | Pareto Securities |